Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan

MT Newswires Live10-17

Kezar Life Sciences (KZR) said Thursday that its board of directors has unanimously rejected an unsolicited takeover bid from Concentra Biosciences saying it "substantially undervalues the company."

The company said Concentra Biosciences sought to acquire all of its outstanding common stock for $1.10 cash per share, as well as the possibility of receiving 80% of the net proceeds from out-license or disposition of Kezar's development programs or intellectual property. It also said Concentra and its affiliates have rapidly accumulated 9.9% of Kezar's outstanding common stock.

As a result of Concentra Biosciences' unsolicited takeover bid and accumulation of shares, the company said its board has adopted a limited duration stockholder rights plan, effective immediately. The board also approved a dividend of one preferred share purchase right for each outstanding share of Kezar's common stock in connection with the rights plan.

Shares of Kezar Life Sciences were down more than 9% in recent premarket activity.

Price: 0.8144, Change: -0.08, Percent Change: -8.98

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476249901?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-17 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476249901","market":"nz","top_or_hot":-1,"title":"Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan","media":"MT Newswires Live","content":"<html><body><p> Kezar Life Sciences (KZR) said Thursday that its board of directors has unanimously rejected an unsolicited takeover bid from Concentra Biosciences saying it \"substantially undervalues the company.\"</p><p>The company said Concentra Biosciences sought to acquire all of its outstanding common stock for $1.10 cash per share, as well as the possibility of receiving 80% of the net proceeds from out-license or disposition of Kezar's development programs or intellectual property. It also said Concentra and its affiliates have rapidly accumulated 9.9% of Kezar's outstanding common stock.</p><p>As a result of Concentra Biosciences' unsolicited takeover bid and accumulation of shares, the company said its board has adopted a limited duration stockholder rights plan, effective immediately. The board also approved a dividend of one preferred share purchase right for each outstanding share of Kezar's common stock in connection with the rights plan.</p><p>Shares of Kezar Life Sciences were down more than 9% in recent premarket activity.</p><p>Price: 0.8144, Change: -0.08, Percent Change: -8.98</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kezar Life Sciences (KZR) said Thursday that its board of directors has unanimously rejected an unsolicited takeover bid from Concentra Biosciences saying it \"substantially undervalues the company.\"...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KZR.AU","symbol_name":"KALAMAZOO RESOURCES LIMITED","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476249901","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476249901","pubTimestamp":1729170682,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kezar Life Sciences  said Thursday that its board of directors has unanimously rejected an unsolicited takeover bid from Concentra Biosciences saying it \"substantially undervalues the company.\"The company said Concentra Biosciences sought to acquire all of its outstanding common stock for $1.10 cash per share, as well as the possibility of receiving 80% of the net proceeds from out-license or disposition of Kezar's development programs or intellectual property. It also said Concentra and its affiliates have rapidly accumulated 9.9% of Kezar's outstanding common stock.As a result of Concentra Biosciences' unsolicited takeover bid and accumulation of shares, the company said its board has adopted a limited duration stockholder rights plan, effective immediately. The board also approved a dividend of one preferred share purchase right for each outstanding share of Kezar's common stock in connection with the rights plan.Shares of Kezar Life Sciences were down more than 9% in recent premark","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KZR.AU":"KALAMAZOO RESOURCES LIMITED","KZR":"Kezar Life Sciences Inc.","BK7095":"多种金属与采矿","BK4139":"生物科技"},"translate_title":"Kezar Life Sciences拒绝Concentra Biosciences收购要约，采用配股计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZR.AU":1,"KZR":0.9},"content_text":"Kezar Life Sciences (KZR) said Thursday that its board of directors has unanimously rejected an unsolicited takeover bid from Concentra Biosciences saying it \"substantially undervalues the company.\"The company said Concentra Biosciences sought to acquire all of its outstanding common stock for $1.10 cash per share, as well as the possibility of receiving 80% of the net proceeds from out-license or disposition of Kezar's development programs or intellectual property. It also said Concentra and its affiliates have rapidly accumulated 9.9% of Kezar's outstanding common stock.As a result of Concentra Biosciences' unsolicited takeover bid and accumulation of shares, the company said its board has adopted a limited duration stockholder rights plan, effective immediately. The board also approved a dividend of one preferred share purchase right for each outstanding share of Kezar's common stock in connection with the rights plan.Shares of Kezar Life Sciences were down more than 9% in recent premarket activity.Price: 0.8144, Change: -0.08, Percent Change: -8.98","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476249901"}